Animal Drug User Fees Reporting - Comment Period

Content

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish
notice in the
Federal Register
concerning each proposed collection of information, including each proposed extension of an existing collection of information,
and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection
provisions of FDA's animal drug and animal generic drug user fee programs.

DATES:

Either electronic or written comments on the collection of information must be submitted by May 22, 2026.

ADDRESSES:

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of May 22, 2026. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before
that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring
that your comment does not include any confidential information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing
process. Please note that if you include your name, contact information, or other information that identifies you in the body
of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” Instructions: All submissions received must include the Docket No. FDA-2026-N-2365 for “Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees.” Received comments, those filed in a timely manner (see ADDRESSES ), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available,
submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The
Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second
copy, which will have the claimed confidential information redacted/blacked out, will be available

  for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly
  available, you can provide this information on the cover sheet and not in the body of your comments and you must identify
  this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with
  21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets,
  see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts
and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT:

Kelly Covington, Office of Operations, Food and Drug Administration, 5001 Campus Drive, College Park, MD 20740, 240-402-5661, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

Under the PRA (44 U.S.C. 3501-3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB)
for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and
5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide
information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide
a 60-day notice in the
Federal Register
concerning each proposed collection of information, including each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed
collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity
of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected;
and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated
collection techniques, when appropriate, and other forms of information technology.

Animal Drug and Animal Generic Drug User Fee Programs

OMB Control Number 0910-0540—Extension

This information collection helps support implementation of the Animal Drug User Fee Act of 2003 (ADUFA) (Pub. L. 108-130)
and Animal Generic Drug User Fee Act of 2008 (AGDUFA) (Pub. L. 110-316), established in sections 740 and 741 of the Federal
Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C 379j-12 and 21 U.S.C. 379j-21), respectively. Under ADUFA, FDA assesses
and collects user fees for certain new animal drug applications and supplements, products, establishments, and sponsors of
new animal drug applications and/or investigational new animal drug files. The ADUFA program is currently reauthorized through
September 30, 2028, and FDA efforts to engage interested stakeholders in the 2028 reauthorization is ongoing. More information
regarding the ADUFA program can be found at https://www.fda.gov/industry/fda-user-fee-programs/animal-drug-user-fee-act-adufa, including current user fee rates applicable to animal drug submissions. Under AGDUFA, FDA assesses and collects user fees
for certain abbreviated (generic) new animal drug applications, supplements, and generic investigational new animal drug file
submissions, products, and sponsors of generic new animal drug applications and/or generic investigational new animal drug
files. The AGDUFA program is currently reauthorized through September 30, 2028, and FDA efforts to engage interested stakeholders
in the 2028 reauthorization is ongoing. More information regarding the AGDUFA program can be found at https://www.fda.gov/industry/fda-user-fee-programs/animal-generic-drug-user-fee-act-agdufa, including current user fee rates applicable to generic animal drug submissions.

These user fee program resources support FDA's responsibilities to ensure that new animal drugs are safe and effective for
the animals, as well as ensuring the safety of food from treated animals.

Sponsors of new animal drug applications complete a user fee cover sheet and submit it through FDA's Center for Veterinary
Medicine's (CVM, the Center) eSubmitter. The Animal Drug User Fee cover sheet (Form FDA 3546) is designed to collect the minimum
necessary information to determine whether a fee is required for the review of an application or supplement or whether an
application fee waiver was granted, to determine the amount of the fee required, and to ensure that each animal drug user
fee payment is appropriately linked to the animal drug application for which payment is made. The form, when completed electronically,
results in the generation of a unique payment identification number used by FDA to track the payment. The information collected
is used by CVM to initiate the administrative screening of new animal drug applications and supplements.

Similarly, sponsors of abbreviated new animal drug applications and certain generic investigational new animal drug file submissions
also complete a user fee cover sheet and submit it through CVM's eSubmitter. The AGDUFA cover sheet (Form FDA 3728) is also
designed to collect the minimum necessary information to determine whether a fee is required for review of an application
or submission to an investigational file, to determine the amount of the fee required, and to ensure that each animal generic
drug user fee payment is appropriately linked to the abbreviated new animal drug application or generic investigational new
animal drug file submission for which payment is made. The form, when completed electronically, results in the generation
of a unique payment identification number used by FDA to track the payment. The information collected is used by CVM to initiate
the administrative screening of abbreviated new animal drug applications and certain generic investigational new animal drug
file submissions.

Both sections 740 and 741 of the FD&C Act provide for waivers, reductions, and exemptions of fees. To assist respondents with
submitting requests for waivers or reductions of ADUFA user fees, we developed guidance for industry (GFI) #170 entitled “Animal
Drug User Fees and Fee Waivers and Reductions” (April 2023), available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions. This document discusses the types of fees FDA is

  authorized to collect under section 740 of the FD&C Act, and how to request waivers or reductions from these fees. Further,
  this guidance also describes what information FDA recommends be submitted in support of a request for a fee waiver or reduction,
  a request for reconsideration of denial of a fee waiver or reduction request, or an appeal of the denial decision in accordance
  with 21 CFR 10.75; how to submit such a request or appeal; and FDA's process for reviewing such requests or appeals.

Similarly, we developed guidance for industry (GFI) #199 entitled “Animal Generic Drug User Fees and Fee Waivers and Reductions”
(May 2009), available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions. This document discusses the types of fees FDA is authorized to collect under section 741(a)(1) of the FD&C Act, and how to
request waivers or reductions from these fees. Further, this guidance also describes what information FDA recommends be submitted
in support of a request for a fee waiver or reduction, a request for reconsideration of denial of a fee waiver or reduction
request, or an appeal of the denial decision in accordance with 21 CFR 10.75; how to submit such a request or appeal; and
FDA's process for reviewing such requests or appeals.

We use the information submitted by respondents to determine whether requests for waiver or reduction of user fees, reconsideration
requests, or appeals may be granted.

FDA estimates the burden of this collection of information as follows:

| FD&C act section; activity | FDA form No. | Number of
respondents | Number of
responses perrespondent | Total annual responses | Average burden
per response | Total hours |
| --- | --- | --- | --- | --- | --- | --- |
| User fee cover sheets, by type | | | | | | |
| 740(a)(1); Animal Drug User Fee cover sheet | FDA 3546 | 7 | 2 | 14 | 0.5 (30 minutes) | 7 |
| 741(a)(1); Animal Generic Drug User Fee cover sheet | FDA 3728 | 22 | 2.4 | 53 | 0.5 (30 minutes) | 26.5 |
| Waiver and other requests, by type | | | | | | |
| 740(d)(1)(A); significant barrier to innovation | N/A | 65 | 1 | 65 | 2 | 130 |
| 740(d)(1)(B); fees exceed cost | N/A | 4 | 2 | 8 | 0.5 (30 minutes) | 4 |
| 740(d)(1)(C); free choice feeds | N/A | 4 | 1 | 4 | 2 | 8 |
| 740(d)(1)(D); minor use or minor species | N/A | 78 | 1 | 78 | 2 | 156 |
| 740(d)(1)(E); small business | N/A | 4 | 1 | 4 | 2 | 8 |
| 741(d)(1); minor use or minor species | N/A | 3 | 1 | 3 | 2 | 6 |
| Request for reconsideration of a decision | N/A | 1 | 1 | 1 | 2 | 2 |
| 21 CFR 10.75; Appeal of a decision | N/A | 1 | 1 | 1 | 2 | 2 |
| Total | | | | | | 349.5 |
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | | | | | | |
Our estimated burden for the information collection reflects an overall increase. We attribute this adjustment to an increase
in the number of submissions we have received since our last evaluation. The total number of annual responses is based on
the average number of submissions received by FDA in fiscal years 2022 to 2024. The estimated time we attribute to the hours
per response is based on our experience with the various submissions and reflects the average burden we attribute to all respondents.

Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2026-05620 Filed 3-20-26; 8:45 am] BILLING CODE 4164-01-P

Download File

Download